首页 | 本学科首页   官方微博 | 高级检索  
   检索      


Pericytes augment glioblastoma cell resistance to temozolomide through CCL5-CCR5 paracrine signaling
Authors:Xiao-Ning Zhang  Kai-Di Yang  Cong Chen  Zhi-Cheng He  Qiang-Hu Wang  Hua Feng  Sheng-Qing Lv  Yan Wang  Min Mao  Qing Liu  Yao-Yao Tan  Wen-Ying Wang  Tian-Ran Li  Lin-Rong Che  Zhong-Yi Qin  Ling-Xiang Wu  Min Luo  Chun-Hua Luo  Yu-Qi Liu  Wen Yin  Chao Wang  Hai-Tao Guo  Qing-Rui Li  Bin Wang  Wei Chen  Shuang Wang  Yu Shi  Xiu-Wu Bian  Yi-Fang Ping
Abstract:Glioblastoma (GBM) is a prevalent and highly lethal form of glioma, with rapid tumor progression and frequent recurrence. Excessive outgrowth of pericytes in GBM governs the ecology of the perivascular niche, but their function in mediating chemoresistance has not been fully explored. Herein, we uncovered that pericytes potentiate DNA damage repair (DDR) in GBM cells residing in the perivascular niche, which induces temozolomide (TMZ) chemoresistance. We found that increased pericyte proportion correlates with accelerated tumor recurrence and worse prognosis. Genetic depletion of pericytes in GBM xenografts enhances TMZ-induced cytotoxicity and prolongs survival of tumor-bearing mice. Mechanistically, C-C motif chemokine ligand 5 (CCL5) secreted by pericytes activates C-C motif chemokine receptor 5 (CCR5) on GBM cells to enable DNA-dependent protein kinase catalytic subunit (DNA-PKcs)-mediated DDR upon TMZ treatment. Disrupting CCL5-CCR5 paracrine signaling through the brain-penetrable CCR5 antagonist maraviroc (MVC) potently inhibits pericyte-promoted DDR and effectively improves the chemotherapeutic efficacy of TMZ. GBM patient-derived xenografts with high CCL5 expression benefit from combined treatment with TMZ and MVC. Our study reveals the role of pericytes as an extrinsic stimulator potentiating DDR signaling in GBM cells and suggests that targeting CCL5-CCR5 signaling could be an effective therapeutic strategy to improve chemotherapeutic efficacy against GBM.Subject terms: Cancer microenvironment, CNS cancer, Cancer therapy
Keywords:
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号